Alvydas Mikulskis

Alvydas Mikulskis is a Senior Director of Biomarkers & Imaging at Vertex Pharmaceuticals, based in the Boston, Massachusetts area.1 He is a highly experienced professional with a strong background in bioanalytical and biomarker assay development for biologics and small molecule drugs across various stages of clinical development.

Professional Experience

Mikulskis has held several key positions throughout his career:

• Senior Director, Clinical Biomarkers & Imaging at Vertex Pharmaceuticals (August 2021 - Present)1
• Director, Clinical Biomarkers & Imaging at Vertex Pharmaceuticals (December 2019 - August 2021)1
• Director of Bioanalytical and Biomarker Development at Takeda (April 2018 - December 2019)1
• Principal Scientist and Research Scientist at PerkinElmer Life & Analytical Sciences, Inc. (1998 - 2002)1

Expertise and Skills

Mikulskis is recognized for his:

• Technical expertise in immunoassay technology platforms
• Focus on precision and compliance in preclinical and clinical trials
• Proficiency in Design of Experiments (DOE)
• Six Sigma Green Belt certification1
• Strong analytical, computer, statistics, and troubleshooting skills1
• Leadership in cross-functional teams and commercial partnerships1

Education

Mikulskis has a diverse educational background:

• PhD in Biology from Moscow Institute of Physics and Technology (1986 - 1992)1
• MS in Molecular Biology from Moscow Institute of Physics and Technology (1982 - 1986)1
• Post-doctoral fellowships at Harvard Medical School and the International Institute of Cellular and Molecular Pathology in Brussels1

Achievements

Throughout his career, Mikulskis has:

• Co-authored seven patents and over thirty scientific publications1
• Contributed significantly to biomarker and imaging advancements in drug development
• Successfully led product development teams and implemented cost-saving measures1
• Served as a dedicated supervisor and career mentor for PhD and junior scientists1

Alvydas Mikulskis is known for his collaborative leadership style, innovative approach, and results-oriented focus in the field of biomarker development and clinical imaging.1